RICHLAND, Wash., Aug. 1, 2017 /PRNewswire/ -- IsoRay
Medical [ISR] – Most American men will spend countless
hours researching before making a major purchase whether it is a
car, boat, motorcycle or a summer home. Yet, when it comes to
their health, they merely accept the advice of their
physician.
The American Cancer Association published data shows nearly
200,000 cases of prostate cancer are diagnosed annually with one in
seven men likely to be afflicted by the disease. Often, the options
are either, invasive surgery, or extensive radiation treatment,
both costly options. A treatment that has often been ignored is
brachytherapy, which is not only more cost-effective but typically
results in less treatment side-effects.
Around since the early 1900s, brachytherapy is a form of
treatment that implants "seeds" directly into the tumorous tissue,
these seeds deliver radiation doses to destroy cancer cells at the
tumor site while limiting the damage to nearby healthy tissue. A
recent study, Long-Term Quality of Life in Prostate Cancer Patients
Treated with Cesium-131 by Glaser, et al., published in The
International Journal of Radiation Oncology, Biology and
Physics suggests that the newest brachytherapy isotope,
Cesium-131, is changing the game.
"For far too long, patients have been treated for prostate
cancer based on a medical professionals' familiarity or, in some
cases, due to far greater financial benefits to the physician,"
said Dr. Brian Moran, medical
director of the Chicago Prostate Cancer Center. "This study
reinforces that a new, patient-friendly treatment
exists. Brachytherapy with Cesium-131 leverages the isotope's
short half-life to significantly reduce the duration of long-term
symptoms and side effects."
Alternative brachytherapy isotopes deliver treatment over a
lengthy time period, often with sustained side effects. Many
physicians are starting to believe that Cesium-131, produced solely
by Isoray Medical, is the ideal go-between – offering a highly
targeted, fast-acting treatment with a shorter delivery time (30
days) than other isotopes used for brachytherapy, and, based on the
recently published study, a quicker recovery period and ability for
the patient to maintain his baseline quality of life over the long
term.
The fast-acting nature of the Cesium-131 seed treatment allows
men to quickly recover from the short-term side-effects of
radiation and return to normal urinary, bowel and sexual function
faster than with other brachytherapy isotopes. Along with the
recently published study, a growing body of literature supports
faster recovery when Cesium-131 brachytherapy is utilized.
Since its inception, Isoray has leveraged the expertise in the
Richland, Washington region to
develop a proprietary process for manufacturing the new medical
isotope, Cesium-131. With this advancement, Isoray has identified a
more cost-effective cancer treatment solution for life beyond a
patient's cancer.
About Isoray, Inc.
Isoray, Inc., through its
subsidiary, Isoray Medical Inc., is the sole producer of Cesium-131
brachytherapy seeds, which are expanding brachytherapy options
throughout the body. Learn more about this innovative
Richland, Washington company and
explore the many benefits and uses of Cesium-131 by visiting
www.isoray.com. Join us on Facebook/Isoray. Follow us on
Twitter @Isoray.
Safe Harbor Statement
Statements in this news release
about IsoRay, Inc.'s future expectations, including: the advantages
of our products and their delivery systems, whether the study will
ultimately be completed, the cost effectiveness and side effect
profiles, the other products' efficacy compared to our product, and
the perception by the patient of quality of life outcomes or prove
to be a safe approach compared to other treatment options, and all
other statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing IsoRay, Inc. of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as physician acceptance, training
and use of our products, our ability to successfully manufacture,
market and sell our products, our ability to manufacture our
products in sufficient quantities to meet demand within required
delivery time periods while meeting our quality control standards,
our ability to enforce our intellectual property rights, whether
additional studies are released and support the conclusions of past
studies, whether ongoing patient quality of life results with our
products are favorable and in line with the conclusions of clinical
studies and initial patient results, patient results achieved when
our products are used for the treatment of cancers and malignant
diseases in conjunction with other treatments, successful
completion of future research and development activities, whether
we, our distributors, and our customers will successfully obtain
and maintain all required regulatory approvals and licenses to
market, sell, and use our products in its various forms, continued
compliance with ISO standards as audited by BSI, the success of our
sales and marketing efforts, changes in reimbursement rates,
changes in laws and regulations applicable to our products, and
other risks detailed from time to time in IsoRay, Inc.'s reports
filed with the SEC Securities and Exchange Commission. Unless
required to do so by law, the Company IsoRay, Inc. undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/new-study-shows-brachytherapy-and-cesium-131-isotope-treatment-beneficial-for-prostate-cancer-patients-300497381.html
SOURCE IsoRay Medical